NextGen's H1 2011 Revenues Climb 34 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The NextGen Group today said that revenues for the first half of the year increased 34 percent, leading to a decline in its net loss.

For the six months ending June 30, the company recorded $948,279 in revenues, up from $708,831 a year ago. Its net loss for the period improved to $1.6 million, or $.0002 per share, from $1.7 million, or $.0004 per share, from the first half of 2010.

NextGen ended the half-year with $28,533 in cash and cash equivalents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.